IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Company Overview - IGM Biosciences, Inc. (IGMS) is expected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of +28.7% [3] - Revenues are anticipated to be $0.53 million, which is a decrease of 18.5% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for IGM Biosciences is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.55%, suggesting a bullish outlook from analysts [10] Earnings Surprise Potential - A positive Earnings ESP reading, combined with a Zacks Rank of 2 (Buy), indicates a strong likelihood that IGM Biosciences will beat the consensus EPS estimate [11][8] - Historically, IGM Biosciences has beaten consensus EPS estimates two out of the last four quarters [13] Industry Context - Praxis Precision Medicines, Inc. (PRAX), another company in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $2.96 per share, with revenues projected at $0.48 million, down 7.7% year-over-year [17] - Praxis has an Earnings ESP of -1.75% and a Zacks Rank of 3 (Hold), making it difficult to predict a beat on the consensus EPS estimate [18]